Glass and Glass-Ceramic Scaffolds: Manufacturing Methods and the Impact of Crystallization on In-Vitro Dissolution by Nommeots-Nomm, Amy & Massera, Jonathan
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 2
Glass and Glass-Ceramic Scaffolds: Manufacturing
Methods and the Impact of Crystallization on In-Vitro
Dissolution
Amy Nommeots-Nomm and Jonathan Massera
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.70242
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Glass and Glass-Ceramic Scaffolds: Manufacturing 
Methods and the Impa t of Crystalliz tion on 
Dissolution
Amy Nommeots-Nomm and Jonathan Massera
Additional information is available at the end of the chapter
Abstract
Synthetic biomaterials mimicking bone morphology have expanded at a tremendous 
rate. Among all, one stands out: bioactive glass. Bioactive glasses opened the door to 
a new genre of research into materials able to promote the regeneration of functioning 
bone tissue. However, despite their ability to promote cell attachment, proliferation and 
differentiation, these materials are mainly used as granules. However to promote loaded 
and sustained bone repair, a 3D structure, with open and highly interconnected pores, is 
desirable. 3D scaffolds are generally produced into green bodies via various techniques. 
The particles are then bound together via sintering. However, the highly disrupted silica 
network of the typical bioactive glasses composition leads to crystallization. Therefore, 
sintering of the most commonly used bioactive glass compositions (i.e. 45S5 and S53P4) 
leads to partly to fully crystallize bodies. The impact of crystallization on bioactivity still 
leads to large debate among the scientific community. Does crystallization reduce or 
suppress the materials bioactivity? Within this chapter, the processing routes for scaf-
fold manufacture are presented, as well as an introduction to the thermal processing 
of glasses to form glass and glass-ceramics and the consequent effect on bioactivity is 
discussed.
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1. Introduction
With the ageing and continuous growth of the population, surgeons face an increas-
ing number of operations aiming to replace and/or repair tissue that has been damaged 
through disease and trauma [1]. According to the International Osteoporosis Foundation, 
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incidence of fracture, for example, is anticipated to increase by 240% in women and 310% 
in men by 2050 [http://www.mdbuyline.com/research-library/articles/bone-graft-substi-
tutes-bone-matrix-cost/, visited last April 2016]. This factor is expected to drive the rise in 
the global bone graft market. Bone regeneration market was evaluated at USD 2.35 billion 
in 2014 and is expected to rise to USD 3.48 billion by 2023, as reported in transparency 
market research [http://www.transparencymarketresearch.com/pressrelease/bone-grafts-
substitutes-market.htm, visited June 2017]. The gold standard in bone grafts is, at present, 
the use of allograft. An allograft is a tissue received from a donor which is demineralised 
before use, thus, genetically different than an autograft (where tissue comes from the 
patient itself). However, a risk of infection is associated with such practices. To overcome 
the infection risk, the allograft tissue must be pre-treated. Techniques used are tissue freez-
ing, freeze drying and sterilization. The average cost per procedure was estimated to be 
USD 3154.
Bioceramics, pertaining to their excellent biocompatibility and higher mechanical properties 
compared to polymers or metals, have always been regarded as the most promising bioma-
terials for hard tissue repair. The advantage of bioceramics lies in their wide tissue/implant 
response: from being nearly inert to bioactive depending on their composition. A subset of 
bioceramics which have expanded at a tremendous rate in the past decade are bioactive glasses. 
These materials support not only osteoconduction (growth of bony tissue at the surface of the 
implant) but also osteoinduction (acceleration of new bone formation by chemical means) [2]. 
Bioactive glasses have, now, been used widely clinically especially in dental and bone repair 
applications.
For the repair and regeneration of bone defects, tissue engineering strives to produce 3D con-
structs that can support mechanical load and provide a template in which cells can migrate 
and colonized. The optimum attribute of a 3D scaffolds are summarized as follow:
• The biomaterials should not only be biocompatible but must support cell adhesion and prolif-
eration. The material should be at minimum osteoconductive but ideally osteoinductive.
• The biomaterials should resorb over time. The resorption rate of the implant should match 
as closely as possible the regrowth of the new tissue.
• The implant should be porous with an open interconnect structure to allow fluid penetra-
tion, angiogenesis and cell proliferation. In general, interconnected pores of at least 100 μm 
and an open porosity of over 50% is considered the minimum requirement for tissue 
 ingrowth [3-5]. Optimally, it is reported that the construct should have pores within 100–
500 μm and an overall porosity of over 90%. However an increase of porosity comes at the 
expense of mechanical strength [6].
• The mechanical properties, which is mainly function of the porosity and the pores or-
ganisation, should be tailored to the site of implantation, i.e. similar to cancellous bone 
in non-load bearing applications and similar to cortical bone in load-bearing applica-
tions. In all case, the mechanical properties should be maintained throughout the bone 
reconstruction.
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2. Scaffold fabrication
2.1. Foamed morphology processing
2.1.1. Porogen
Porogen processing is a method in which glass powders are mixed with a polymer bead used 
as a ‘space holder’, and packed into a mould. The polymer is then burnt away in a two stage 
sintering process to create porous scaffold. This process relies on using a combustable poly-
mer and sufficient oxygen flow to gain complete burn out during sintering, if complete burn 
out is not achieved it can result in inhomogeneous scaffolds being formed with a porosity 
gradient. The scaffolds tend to have limited porosity of up to 50% [7].
2.1.2. Freeze casting
Freeze casting is a traditional ceramic foam processing method, which is based upon the for-
mation of an aqueous slurry where ice crystals are formed in the direction of freezing. Under 
vacuum, the ice crystals are then sublimated to leave a porous green body which is then sin-
tered [8]. This was initially developed in 2011 for use with hydroxyapatite, but has since been 
used with various glass and glass-ceramic compositions [9-11]. The scaffolds produced tend 
to have small pores (up to 100 μm) with low levels of interconnection, with consequently high 
strengths. Due to the small pores, they have not been significantly investigated in either the 
glass or glass-ceramic field for bone repair.
2.1.3. Foam replica process
The foam replica process employs a polymeric foam, commonly made of polyurethane, to 
act as a template for a glass slurry to create scaffolds with a foamed morphology. The foam 
is soaked in a glass suspension, and dried. By completing multiple cycles of infiltration and 
drying the wall thickness of the scaffolds can be increased, however, the shape obtained is still 
dependent upon the foam itself. The sintering process is then completed in two stages, firstly to 
burn out the polymer foam, and secondly to sinter the particles to form a continuous construct. 
The foam template is key within this process, its pore shape, size, and distribution all control 
the outcome of the scaffolds produced. The mechanical properties of the scaffolds produced 
via this technique are predominately dependent upon the particle distribution within the foam 
prior to burnout, which is controlled by the stability and concentration of the suspension used.
The process was first adopted to produce glass ceramics from the 45S5 composition in 2006. 
Scaffolds were produced from 45S5 glass powder, then sintered at 1000°C for 1 hour, form-
ing fine crystals of Na
2
Ca
2
Si
3
O [12]. It was then adapted by Fu et al. [13] using the 13-93 glass 
composition which were kept amorphous post sintering (54.6 SiO
2
, 22.4 CaO, 6 Na
2
O, 1.7 P
2
O
5
, 
7.9 K
2
O, 7.7 MgO in mol%). The scaffolds met many of the requirements for bone regenera-
tion, with a reported porosity of 85 ± 2%, interconnected pores between 100 and 500 μm, and 
compressive strengths of 11 ± 1 MPa. These values are similar to those of human trabecular 
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bone and outperformed other glass-ceramic foams reported in literature at the time [13]. This 
could be attributed to their optimisation of glass loading within the slurry. Their particle size 
distribution (modal size of 2 μm) allowed for good particle packing within the green body 
enhancing sintering. Combining this with the sintering window provided by the 13-93 com-
position allowing viscous flow without crystallisation during sintering, leads to the formation 
of dense struts with limited distortion of the foams morphology.
Table 1 summarises the variety of glass and glass ceramics that have been produced via this 
method; as shown there are large differences between the properties obtained but it high-
lights the flexibility of the processing method. A limitation of the foam replica process is that 
excess slurry can become trapped inside the sacrificial polymer foam after infiltration, which 
can be difficult to remove prior to burnout and sintering. It has to be squeezed out and if 
excess slurry remains, the structure produced will be heterogeneous with a porosity gradient 
being formed. Even with optimum processing, the foam replica method can leave struts with 
hollow centres which reduce the mechanical properties and performance of the scaffolds [14].
2.1.4. Gel-cast foaming
Sepulveda and Binner [15] first used gel-cast foaming to create porous ceramics. Rather than 
using a foam template, as used within the foam replica process, the ceramic slurry was foamed 
under vigorous agitation with the aid of a surfactant. The process used in-situ polymerisation 
of an organic monomer, such as methacrylamide, to form a gel and stabilise the foam. The 
polymer was then burnt out during the sintering cycle. Wu et al. [16] adapted this gel-casting 
process to manufacture scaffolds using the composition ICIE16 (49.46% SiO
2
, 36.27% CaO, 6.6% 
Na
2
O, 1.07% P
2
O
5
 and 6.6% K
2
O, in mol%). The process was based upon in situ polymerisa-
tion of acrylamide by using a cross-linker, surfactant and initiator. Although this alternative 
processing method avoided the ‘hollow strut’ issues associated with the foam replica process 
it was limited in its ability to be scaled up to higher volume manufacture due to the small gela-
tion window of the polymer used, it was also shown to precipitate sulphur rich crystals upon 
the glass surface. The scaffolds produced by Wu et al. [16] had porosities of 79%, with modal 
pore diameters of 379 μm and compressive strength of 1.9 MPa. These values were a factor of 10 
lower than those reported by Fu et al. for foam replica scaffolds manufactured from 13-93 [13].
The gel-casting process was later adapted by Nommeots-Nomm et al. by using the thermally con-
trolled gelation of gelatin to increase the processability of the system and stop unwanted sulphur 
byproducts. Amorphous scaffolds with foam morphologies were produced with porosities of 
75% with modal pore interconnects between 100 and 150 μm. Scaffolds were produced from three 
glass compositions ICIE16, PSrBG (44.5 SiO
2
, 17.8 CaO, 4 Na
2
O, 4.5 P
2
O
5
, 4 K
2
O, 7.5 MgO and 17.8 
SrO mol%) and 13-93 with compressive strengths of 3.4 ± 0.3, 8.4 ± 0.8 and 15.3 ± 1.8 MPa respec-
tively, higher than values presented in literature for equivalent foamed scaffolds. In-vivo analysis 
within a femoral head defect in a rabbit model supported growth across 12 weeks; however, the 
rate of scaffold degradation raised some questions about its suitability for a human model [26].
This process has also been adapted for the production of glass ceramics and more recently glass 
ceramics from pre-ceramic polymers. Fiocco et al. used pre-ceramic polymers to  produce wollas-
tonite diopside scaffolds with 77% open porosity and compressive strengths of 1.8 ± 0.3 MPa [27].
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Composition name Composition used/
mol %
Pore size/μm Porosity/% Compressive 
strength/MPa
Reported bioactivity
Glass-ceramics
CEL2 [17] 45% SiO
2
, 3% P
2
O
5
, 26% 
CaO, 7% MgO, 15% 
Na
2
O, 4% K
2
O
100–300 75 1 ± 0.4 HA reported after 1 
week
Borosilicate® [18] P
2
O
5
–Na
2
O–CaO–SiO
2
200–500 95 0.06 ± 0.01 HA reported after 
with 72 hours
[19] 57SiO
2
–34CaO–
6Na
2
O–3Al
2
O
3
 crystal 
formation: CaSiO
3
Mean: 240 56 ± 6 18 Not reported
45S5 [12] Crystallised phase: 
Na
2
Ca
2
Si
3
O
9
510–720 89–92 0.27–0.42 HA reported after 
3 days
45S5 [20] Crystallised phase: 
Na
2
Ca
2
Si
3
O
9
Not reported 90 0.4 Not tested
45S5 [21] Na
6
Ca
3
Si
6
O
18
 and 
Na
2
Ca
4
(PO
4
)
2
SiO
4
25–600 61 ± 3 13.78 ± 2.43 HA reported after 
7 days
Glass
Zn-doped 
borosilicate [22]
6Na
2
O, 8K
2
O, 8MgO, 
22CaO, 36B
2
O
3
, 18SiO
2
, 
2P
2
O
5
;
Zn substitution at 1.5, 5 
and 10 wt.% ZnO
200–400 80–92 ± 7 Not reported HA reported after 
90 days,8 weeks in a 
rat calvarial defects, 
glass doped with 5% 
Zn enhanced bone 
formation
13-93 doped with 
copper [23]
6Na
2
O, 8K
2
O, 8MgO, 
22CaO, 36B
2
O
3
, 18SiO
2
, 
and 2P
2
O
3
 (mol%)
Copper doping at 0, 1 
and 3 wt.%
100–300 85 ± 3 Not reported HA reported after 
90 days
13-93 doped with 
cobalt [14]
wt.%: 53SiO
2
, 6Na
2
O, 
12K
2
O, 5MgO, 20CaO, 
and 4P
2
O
5
Cobalt doping at 0 
wt.%, 1 wt.% and 5 
wt.% CoO
200–400 89–91 2.3–4.2 HA reported after 
3 days
13-93 [13] 53SiO
2
, 6Na
2
O, 12K
2
O, 
5MgO, CaO, 4P
2
O
5
 
wt.%
100–500 85 ± 2 11 ± 1 Within 7 days
13-93B1 [24] 6% Na
2
O, 8% K
2
O, 8% 
MgO, 22% CaO, 18% 
B
2
O
3
, 36% SiO
2
, 2% P
2
O
5
Mean 500 78 5.1 ± 1.7 HCA within 30 
days, to non critical 
osseous defect model 
in a rabbit, one in 
the femoral head, 
one in radius bone 
supported regrowth
[25] 22 CaO, 6 Na
2
O, 8 
MgO, 8 K
2
O, 18 SiO
2
, 36 
B
2
O
3
, and 2 P
2
O
5
250–500 72 ± 3 6.4 ± 0.1 HA reported after 
7 days
Table 1. Summary of the glass and glass-ceramic scaffolds reported in literature produced via the foam replica method.
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2.2. Additive manufacturing techniques
2.2.1. Selective laser sintering
Selective laser sintering (SLS) is a layer-by-layer additive manufacture technique capable of 
manufacturing green bodies. Glass particles are most commonly mixed with a thermoplastic 
binder after which, a laser locally heats the areas of interest creating a layered green body, the 
powder bed then drops down and another layer of particulate is dispersed and then selec-
tively bound. Unbound particles are removed and the green body is sintered using a two 
stage process to remove the binder and merge the particles together. As with most powder 
based 3D printing technique, its advantages are that complex or challenging geometries can 
be manufactured. However, it is limited by the accuracy of the laser, the size of construct that 
can be produced, the detail of the features that can be formed, and the ability to completely 
burn out the binder without leaving residual porosity [28].
One study utilising SLS by Velez et al. reports scaffolds of 13-93 glass, with particles of sizes up 
to 75 μm, using stearic acid as a binding agent. The scaffold with 50% porosity had strengths 
of 40 ± 10 MPa post-sintering [29]. Work by Kolan et al. [28] reported mechanical properties 
within the same range as Velez et al. [29] of 41 MPa for 50% porosity. Their work looked at 
optimising the process by reducing the binder concentration and particle size, and increasing 
the laser power to increase processing speed. However, the time to produce scaffolds com-
pared with competing 3D printing techniques, such as direct ink writing was still much longer.
2.2.2. Stereolithography
Stereolithography is a slurry-based 3D printing technique; a bed is flooded with a homog-
enous dispersed slurry of particles containing a photocurable polymer. A laser is then used to 
cure the polymer locally to build a layer of the desired design. The bed is then dropped down 
and flood again with the slurry, and a second layer is cured into place. The stereolithography 
process offers the freedom to design and fabricate very complex shapes, but again as with 
selective laser sintering the processing times are slow.
45S5 glass-ceramic scaffolds have been successfully printed into a variety of pore design and 
geometries [30]. They found that, for a diamond-like structure, reducing the pore size from 
700 to 400 μm while maintaining the same overall porosity (~60 vol%) increased the mechani-
cal strength from 3.5 to 6.7 MPa respectively.
2.2.3. Robocasting
Robocasting is another ‘3D printing’ method being used to manufacture porous scaffolds 
from bioactive glasses. Originally developed in 1998 by Cesarano et al., it can be described as 
a solution based extrusion process controlled by computer aided design [31]. The robocast-
ing technique relies on the formulation of glass loaded inks which can be extruded through 
fine diameter nozzles. An example of the scaffolds produced is shown in Figure 1. The first 
development of this technique relied on manipulating the interparticle forces within particle 
loaded suspensions to create inks with the correct rheological properties for printing [31]. 
Now binder ‘inks’ are formulated with the correct rheological properties to act as a carrier of 
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the particles which bind them together prior to sintering. An ideal ink would be easy to mix, 
allow for high glass powder loadings while maintaining a printable viscosity, have pseudo-
plastic rheological properties, and yield strength and storage modulus high enough to be able 
to withstand the weight of multiple layers of scaffolds and the spanning distance.
Robocasting is the most commonly used 3D printing technique for bioactive glasses. This is for 
a number of reasons: the speed of fabrication; the ease at which inks can be produced; and the 
capability and accessibility of the machines. This enables the printing of inks with high glass 
loading, which produce scaffolds with low strut porosity, enhancing their mechanical properties.
The first robocasting paper published from a bioactive glass was by Fu et al. using 13-93 
glass and Pluronic F-127 surfactant as a carrier ink [32]. Pluronic F-127 is a block co-poly-
mer surfactant with thermally reversing rheological behaviour, made up of poly(ethylene 
oxide)-poly(propylene oxide)-poly(ethyleneoxide) tri-blocks (PEO-PPO-PEO) (HO(C
2
H
4
O)
a(C
3
H
6
O)b(C
2
H
4
O)c). Pluronic F-127 can be dissolved in water, forming a stable suspension 
via steric repulsion of the –OH groups [33-35]. Due to its thermally reversible properties it 
enables easy mixing of glass particle at low temperatures while enabling the formation of 
high modulus, and high stiffness pseudoplastic inks at room temperature. Since Fu’s initial 
work, groups have worked with a variety of different glass and binder chemistries, sum-
marised in Table 2.
Figure 1. An example of robocast scaffolds produced from ICIE16 bioactive glass (authors own).
Glass used Max glass 
loading/vol %
Ink chemistry and 
(dispersant)
Strut size/μm Pore size/μm Porosity/% Compressive 
strengths/MPa
6P53B [32] 30 F-127 (water) 100 500 60 136 ± 22
13-93B3
13-93 [38]
45 Ethyl cellulose/PEG 
(ethanol)
300 ± 20 420 ± 30 48 ± 3 65 ± 11
142 ± 20
13-93 [39] 40 F-127 (water) 330 300 47 86.9 ± 9
45S5 [40, 41]* 45 Carboxymethyl 
cellulose (water)
250–300** Not available 63 ± 3 13 ± 1
*Not amorphous post sintering.
**Values not reported, therefore, measured using imageJ from the published SEM images available.
Table 2. Summary of current literature on scaffolds produced via direct ink writing.
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The homogeneity of the ink, particle packing, sintering process, strut size and spacing all con-
tribute to the scaffolds overall mechanical properties. Due to the periodically arrange struc-
ture the strengths achieved are substantially higher than other scaffold processing methods, 
offering strengths in the range of cortical bone instead of cancellous [36].
Glass-ceramic scaffolds have also been produced via this technique. Roohani-Esfahani et al. 
produced scaffolds of various designs from a heat treated sol-gel Sr doped Ca
2
ZnSi
2
O
7
 (HT) 
composition. They reported high strengths in excess of 100 MPa with high fatigue and crack 
resistance created by the multiphase composition [37].
3. Sintering and crystallization
One point, that all scaffold processing technique have in common, is the necessity for a sin-
tering step. Sintering is a thermally induced phenomenon where, initially, the particles will 
undergo viscous flow. Viscous flow will ultimately lead to reorientation of the glass particles 
and neck growth. At a later stage, the contact between particles will grow and the pores will 
shrink resulting in a dense body where, usually, some closed pores will become trapped. 
Trapped pores are characteristically in the sub-micron range. However, in the case of glass 
and more particularly bioactive glasses, the heating process may induce crystallization.
The crystallization of the two most used and FDA approved glass, i.e. 45S5 and S53P4, has 
been studied in details by Massera et al. [42]. In this study, the activation energy for viscous 
flow as well as the activation energy for crystallization was quantify for fine (<45 μm) and 
coarse (300–500 μm) glass particles. As expected, the activation energy for viscous flow was 
independent of the glass particle size and ranged between 750 and 800 kJ/mol. On the other 
hand, the activation energy (Ec) for crystallization was found to be constant with respect to 
glass particles size, for the glass S53P4 with a value around 300 kJ/mol. In the case of the glass 
45S5, Ec was found to decrease, from 338 to 230 kJ/mol, with increasing particles size. This 
is typically an indication of a change in the crystallization dimensionality with respect to the 
crystal size. The Jonhson-Mehl-Avrami exponent, which gives an indication of the dimension-
ality of the primary crystal phase, was calculated. While a value of ~1 was constantly derived 
for the glass S53P4, independently of the technique used (Augis and Bennett equation, Ozawa 
and isochronal method), the value was found to change from 0.8 to 2.8 when using the Augis 
and Bennett equation. Not only the ‘n’ exponent was found to change as a function of particles 
size but it also varied depending on the method employed. Such variation in the JMA expo-
nent calls for questioning the Johnson-Mehl-Avrami crystallization model. The JMA model 
validity was tested using the methods proposed by Malek and Mitsuhashi [43]. While the JMA 
model was validated for the glass S53P4, the JMA model was found to be unsuitable to the 
crystallization of glass 45S5. Overall, both glass S53P4 and 45S5 were found to be fragile glass, 
i.e. a small change in temperature leads to a significant change in viscosity. The activation 
energy for viscous flow is high indicating that sintering or fibre drawing at moderate temper-
ature will be virtually impossible. Crystallization is surface initiated (n ~ 1) for the glass S53P4. 
Figure 2a presents a SEM image of the glass surface after a heat treatment at 730°C for 2 hours 
and Figure 2b presents the crystallized layer thickness as a function of heat treatment time.
Scaffolds in Tissue Engineering - Materials, Technologies and Clinical Applications38
As shown in the SEM image the crystallization initiates at the glass surface with a growth rate 
of about 3.5 μm/min. Such crystallization kinetic will prevent proper sintering of the glass 
particles. Furthermore, one should keep in mind that during scaffolds processing, it is gener-
ally accepted, that small particles size should be used. Decreasing the particles size leads in an 
increase in the surface area and therefore an increase in nucleation sites. Therefore, this glass 
may not be suited for the sintering of amorphous scaffolds.
The crystallization of the glass 45S5, described in [42] seemed to be initiated within the bulk. 
However, it appears that the glass becomes phase separated, with one amorphous phase crys-
tallizing at lower temperatures than the secondary phase. Upon increasing the duration of the 
heat treatment the crystals grew via surface controlled crystallization thereby the elements 
of the secondary phase, at the interface with the crystals, ‘feeds’ the crystal. The formation of 
large pores was also evident during sintering of this glass composition.
The kinetics driving the crystallization of the two most known and clinically used bioactive 
glasses does not permit complete sintering of scaffolds without formation of crystallites.
4. Impact of crystallization on bioactivity
The impact of crystallization on the bioactivity or, more precisely, on the ability of the glass 
to precipitate a HA layer, has been first studied by Peitl Filho et al. [44]. Their conclusion was 
that below 60% crystallinity the ability of the glass 45S5 to precipitate a reactive layer was not 
impaired whereas above 60% crystallinity the reactive layer precipitated at a slower rate. This 
was then confirmed with glass S53P4 by Fagerlund et al. [45]. They demonstrated that when the 
glass particles were heat treated at temperature to maintain the glass fully amorphous a clear 
formation of Si-rich layer, a mixed layer and a Ca–P with a Ca/P = 1.6–1.7 was formed. When 
the glass started to crystallize, the precipitated reactive layer was much thinner and disappeared 
with an increase in heat treatment temperature. Interestingly, at temperature above 750°C a sec-
ondary crystal phase was formed. Upon immersion in simulated body fluid the primary crystal 
Figure 2. SEM image of a glass S53P4 heat treated for 2 hours at 730°C (a) and layer thickness as a function of heat 
treatment time at 730°C (b) (authors own).
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phase, belonging to the combeite composition dissolved, leading to the formation of thick mixed-
layer. However, no Ca–P reactive layer precipitated at the surface of the particles. Furthermore, 
the secondary phase was found insoluble in simulated body fluid. Therefore, it can be concluded 
that while the bioactivity is not fully suppressed in this silicate-bioactive glasses a clear decease 
in the ability of the glass to form a HA layer was greatly slowed down. One should keep in mind 
that the precipitation of such layer is only a small contribution of the glass towards the bioactiv-
ity and, as such, is not sufficient to make firm conclusion regarding the bioactivity of the materi-
als in-vivo. Nonetheless, it remains that one of the most interesting aspects of bioactive glasses is 
the release of therapeutic ions in a control fashion and this cannot be controlled when the glass is 
crystallized in an uncontrolled manner, as it is the case during sintering of rapidly crystallizing 
glasses. Such uncontrolled crystallization also raises the question about the ability to confidently 
reproduce similar microstructure, which would be key in production for the clinic.
Other well-known and promising bioactive glasses for bone regeneration belongs to the phos-
phate composition. Ahmed et al. [46] Neel et al. [47], as well as Massera et al. [48–50], have 
developed phosphate glass composition that not only can promote cell attachment and pro-
liferation but that can also be shaped into fibres. Nevertheless, a thorough understanding of 
the glass crystallization is necessary in order to understand the possibilities and limitations of 
these glasses. Massera et al., developed a glass within the 50P
2
O
5
–(40–x)CaO–xSrO–10Na
2
O 
that can promote the activity of human gingival fibroblasts [49]. The crystallization kinet-
ics of these glasses along with the in-vitro dissolution in simulated body fluid of partially to 
fully crystallized glasses has been studied in [50]. If heat treated at temperature below their 
crystallization, the reactive layer precipitation rate remained unchanged. Particles that were 
partially crystallized were ground to 125–250 μm particles size. The crystallization was found 
to initiate at the surface of the glass particles. During the grinding process the particles were 
fractured and revealed surfaces that were crystallized and some surfaces that were amor-
phous. Figure 3 shows the SEM image of crushed glass particles with an amorphous surface 
and a rounded crystallized surface after 72 hours of immersion in simulated body fluid.
Figure 3. SEM micrograph of glass with composition 50P
2
O
5
–20CaO–20SrO–10Na
2
O heat treated at 40°C below the 
crystallization temperature Tp (from DTA) for 30 min and immersed for 72 hours in simulated body fluid (reproduced 
from Massera et al. [49] with permission).
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It appears clear on the SEM micrographs that the precipitation of the reactive layer is not sup-
pressed. However, the reactive layer is only visible at the amorphous surface. This indicates 
that fully crystallized phosphate glasses will not support the precipitation of reactive layer.
A fully crystallized phosphate glass (50P
2
O
5
–40CaO–10Na
2
O) was also immersed in simu-
lated body fluids. No reactive layer could be detected at the surface of the glass particles. 
The phosphate and calcium ions released within the solution were quantified by ICP and are 
presented in Figure 4.
As expected the amorphous glass released phosphate ions and consume the calcium. This is 
attributed to the congruent dissolution of the phosphate glass and subsequent precipitation 
of a calcium phosphate reactive layer with a Ca/P ratio of 1. The crystallized glass, however, 
released a greater amount of P whereas the Ca remained constant within the accuracy of the 
measurements. From XRD the fully crystallized glass is composed of NaCa(PO
3
)
3
 crystals and 
Ca(PO
3
)
2.
 The NaCa(PO
3
)
3
 crystals which is the primary crystal phase is more soluble than the 
secondary phase. The large release of phosphorus ions leads to a drastic decrease in the pH, 
which suppress the precipitation of the reactive layer [50].
Therefore, one can say that the impact of crystallization on the in-vitro dissolution can either 
reduce or suppress the precipitation of the CaP reactive layer. Also, one should keep in mind 
that the ion release of the partially to fully crystallized glass will be different than the origi-
nal amorphous composition. The impact of crystallization on the bioactivity is a function of 
the crystal composition, crystal density and the composition of the remaining amorphous 
phase.
Alternative composition, which can be processed into amorphous porous scaffolds, are avail-
able. One example, among others, is the glass 13-93 [51]. This glass has been found to be bioac-
tive and to have a wide hot forming window and a viscosity/temperature relationship enabling 
sintering prior to the crystallization. More recently, another family of glass composition which 
is gaining interest are borosilicate. Fu et al., taken as an example, processed 13-93 glass com-
position were the SiO
2
 was partially to fully replaced by B
2
O
3
 [52]. They demonstrated that the 
Figure 4. [P] (a) and [Ca] (b) concentration in the simulated body fluid when the glass and the corresponding crystallized 
are immersed for various times (authors own).
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precipitation of the hydroxyapatite was accelerated with the presence of boron. However, the 
cell proliferation, in-vitro, was greatly reduced both in static and dynamic test. Nevertheless, 
the in-vivo outcome of these materials was positive [52]. Other researcher are attempting to 
develop borosilicate glass based on the fast dissolving bioactive 45S5 and S53P4 [53].
5. Conclusion
The current need for an off the shelf bone repair product is evident, and due to the current 
ageing demographic that need is growing. Literature presents a wide variety of bioactive 
glass and glass-ceramic compositions with tailored bioactivity and therapeutic effects suitable 
for bone repair. A huge wealth of different scaffold processing methods have been employed 
in the last 10 years, offering different morphologies, porosities and mechanical strengths. 
Previously these materials have been limited by their mechanical strength - porosity rela-
tionships. However, since 2011, with the growth of 3D printing, scaffolds with compressive 
strengths in the range of cortical bone have now been developed.
The common point of all scaffolds processing technique is the need for a sintering step at 
medium to elevated temperature. Sintering of bioactive glass is known to often lead to glass 
crystallization. Understanding the relationship between crystallization and bioactivity of bio-
active glasses is of paramount importance. The available results demonstrate that the impact of 
the crystallization can have various effect on bioactivity depending upon the glass  composition 
in question. While partial to full crystallization of the most known and widely used silicate 
bioactive glasses (S53P4 and 45S5) leads to a decrease in the bioactivity. Metaphosphate bioac-
tive glasses have been shown only to precipitate HA on remaining amorphous surfaces.
Regardless of the glass composition, partial to full crystallization leads to drastic change in 
the ions releasing rate and the dissolution mechanism. The dissolution behaviour of the crys-
tallized phases is then different to that of the original glass. The crystallization of bioactive 
glasses is difficult to control, therefore leading to large variation from samples to sample 
disabling full prediction of the materials degradation.
The impact of glass crystallization on the bioactivity is dependent upon the crystals composi-
tion, size and density. Therefore, a better understanding of the crystallization mechanism of 
these glasses may allow for predictable ion release and enhanced mechanical properties.
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